repository
항암화학요법을 시행받은 위암환자의 예후인자 분석
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.advisor | 최진혁 | - |
| dc.contributor.author | Jeong, Seong Hyun | - |
| dc.date.accessioned | 2019-10-21T07:11:37Z | - |
| dc.date.available | 2019-10-21T07:11:37Z | - |
| dc.date.issued | 2009-08 | - |
| dc.identifier.other | 10019 | - |
| dc.identifier.uri | https://dspace.ajou.ac.kr/handle/2018.oak/17097 | - |
| dc.description | 학위논문(석사)--아주대학교 일반대학원 :의학과,2009. 8 | - |
| dc.description.tableofcontents | ABSTRACT ··················································································· i TABLE OF CONTENTS ···························································· ii LIST OF FIGURES ····································································· iii LIST OF TABLES ······································································ iv ABBREVIATION ·········································································· v I. INTRODUCTION ······································································ 1 II. MATERIALS AND METHODS ············································· 4 A. MATERIALS ··········································································· 4 B. METHODS ·············································································· 4 1. Chemotherapy 2. Immunohistochemical Staining for Drug Resistance- Related Proteins 3. Statistical Analysis III. RESULTS ··············································································· 9 IV. DISCUSSION ········································································19 V. CONCLUSION ·······································································23 REFERENCES ············································································24 국문요약 ·······················································································30 | - |
| dc.language.iso | eng | - |
| dc.publisher | The Graduate School, Ajou University | - |
| dc.rights | 아주대학교 논문은 저작권에 의해 보호받습니다. | - |
| dc.title | 항암화학요법을 시행받은 위암환자의 예후인자 분석 | - |
| dc.title.alternative | Seong Hyun Jeong | - |
| dc.type | Thesis | - |
| dc.contributor.affiliation | 아주대학교 일반대학원 | - |
| dc.contributor.alternativeName | Seong Hyun Jeong | - |
| dc.contributor.department | 일반대학원 의학과 | - |
| dc.date.awarded | 2009. 8 | - |
| dc.description.degree | Master | - |
| dc.identifier.localId | 567886 | - |
| dc.identifier.url | http://dcoll.ajou.ac.kr:9080/dcollection/jsp/common/DcLoOrgPer.jsp?sItemId=000000010019 | - |
| dc.subject.keyword | 항암화학요법 | - |
| dc.subject.keyword | 위암환자 | - |
| dc.subject.keyword | 예후인자 | - |
| dc.subject.keyword | 분석 | - |
| dc.description.alternativeAbstract | Purpose: The present study evaluated the predictive role of Bax, excision repair cross-complementation group 1 (ERCC1), and thymidylate synthase (TS) on clinical outcomes in patients with advanced gastric cancer treated with 5-fluorouracil (5-FU) and platinum palliative chemotherapy. Materials and Methods: One hundred and twenty-eight patients with metastatic or recurrent gastric cancer were treated with a chemotherapy regimen of either 5-FU and heptaplatin (FH) (56 patients) or 5-FU, leucovorin, and oxaliplatin (FOLFOX) (72 patients). Pretreatment tumor biopsy specimens were analyzed for Bax, ERCC1, and TS expression by immunohistochemistry. Results: High expression of Bax, ERCC1 and TS was observed in 49 (38%), 60 (47%), and 48 (38%) patients, respectively. The median overall survival (OS) of patients in total was 10 months. Low expression of Bax was associated with poor OS (median, 9 months vs. 12 months; 2-year, 7% vs. 32%; p=0.0005) in univariate analysis, while expression of ERCC1 and TS was not correlated with patient outcome. The outcome of patients with low expression of Bax was significantly worse in the FOLFOX group (median OS, 9 months vs. 18 months; p=0.0008), without significant difference in the FH group. In multivariate analysis, low expression of Bax was a significant independent predictor of poor OS (p=0.014). Conclusions: Low expression of Bax was significantly associated with the poor survival of patients with metastatic or recurrent gastric cancer treated with 5-FU and platinum chemotherapy. Immunohistochemical staining for Bax with pretreatment biopsy specimen may be useful in selecting FOLFOX regimen as a treatment option for these patients. | - |
- Appears in Collections:
- Graduate School of Ajou University > Department of Medicine > 3. Theses(Master)
- Files in This Item:
- There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
-
- License
- STATISTICS
- Total Visit :3,735,629
- Total Download :1,818
- Today View :13,287
